HIV/AIDS: 'Functional Cure' On The Way?
California-based Sangamo BioSciences, Inc. believes that it has taken HIV/AIDS research to a new height and developed what the firm is calling a "functional cure."
At the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, Ga. March 3 through 6, Sangamo unveiled exciting new data on its HIV/AIDS functional cure research.
In Sangamo's first presentation at the Atlanta conference, the firm showed that its SB-728-T treatment of HIV-infected subjects has led to "durable reconstitution of the immune system" thanks to an increase in CD4+ central memory T-cells (TCM) and CCR5-protected TCM. This is an important development due to TCM being "long-lived, self-renewing cells that have the ability to remember and react against foreign antigens including HIV."
According to Sangamo's March 6 press release, the firm can now utilize certain cell surface marker and gene expression profiles to anticipate which patients will best respond to the SB-728-T treatment.
"These important data extend our understanding of why SB-728-T treatment improves the immune system as well as the conditions required for optimal engraftment of ZFN-modified T-cells," Sangamo's Vice President of Therapeutic Development and Chief Medical Officer Dale Ando, MD, says in the release. "[The data] confirm that SB-728-T meets the key immunologic requirements for immune reconstitution in HIV-infected individuals."
Ando added that he believes the data further shows that Sangamo can better distinguish how to "optimize" its future clinical trials regarding the specialized treatment.
Sangamo's research is particularly groundbreaking in light of the fact that the durable reconstitution of the immune system in HIV-infected subjects has never before been observed after a single treatment stemming from any other therapeutic research, according to Rafick-Pierre Sekaly, Ph.D., co-director and chief scientific officer, The Vaccine & Gene Therapy Institute of Florida (VGTI Florida).
Sekaly's laboratory carried out this analysis.
"Improvement in the overall health of the immune system of HIV-infected individuals, as demonstrated by treatment with SB-728-T, is a key step along the path to developing an immunologic approach to controlling and potentially eliminating the virus," Sekaly says.
An infected person's immune system is affected by HIV through the disease's killing off of CD4+ T cells. Currently, the regimen for HIV/AIDS victims includes a daily treatment with antiretroviral therapy (ART), which suppresses viral load in the blood of most subjects. This treatment, however, does not rid the body of HIV-infected cells and a lot of patients do not see their CD4+ T-cell rising back to normal levels.
"SB-728-T treatment, by eliminating the co-receptor, CCR5, which is necessary for HIV entry to CD4+ cells, is designed to provide a CCR5-negative population of CD4+ T-cells that cannot be infected by HIV but are able to fight opportunistic infections and enable the immune system to control and eliminate the virus," Sangamo's release says. "The data presented today demonstrate that SB-728-T treatment leads to unprecedented durable increases in total CD4+ T cells that are correlated with increases in TCM and ZFN-mediated CCR5-modified TCM. "
Sangamo's President and CEO Edward Lanphier says the company will engage in Phase 2 trials of the SB-728-T treatment, which will build on the earlier research that turned up the announced data. The information garnered from these new trials will be released later this year.
"These exciting data support our development program for SB-728-T as a potential functional cure for HIV/AIDS," Edwards says.
Like what you're reading? Follow @profklickberg.
Bee Venom Kills HIV: Nanoparticle Toxins Hold Amazing Power
Researchers discover nanoparticles loaded with a toxin found in bee venom destroys HIV
AIDS May Be Much Older Than Previously Thought
A new scientific study suggests 'lentiviruses' such as HIV may have had much earlier origins than previously estimated.
HIV, The Next Target Of Trump Administration
As continuous efforts to eradicate HIV are taking place, why does the Trump administration wanted to halt the treatment that has been started by the previous government? What’s the truth behind claims that if the current US President would push this through, it will kill thousands? Find out what authorities have to say
How Do We Reduce HIV Risk? Here Are Experts' Tips
With the continuous efforts to eradicate one of the world's long dreaded disease, can we really do certain precautionary measures to prevent the risk of HIV? What are the necessary steps to prevent transmission of the disease? Find out what experts have to say
HIV Vaccine Cures Five Patients For Seven Months
New AIDS vaccine developed in Spain have reportedly cured 5 patients, helping them remain virus-free for seven months after taking the treatment. In the study, the treatment allowed the patients to stop taking regular antiretroviral (ARV) drugs to suppress HIV symptoms.
MORE IN ITECHPOST
VR-Controlled Robots Stocking Shelves in Japan Convenience Stores
In a certain chain of Japanese convenience stores, robots that are controlled by people in VR will be stocking shelves instead of regular employees.
Spotted in Deep Space: Never Before Seen Four Mystery Objects
A few mysterious objects that haven't been seen until now have recently been spotted in deep space thanks to massive radio telescopes.
Learn the Ropes of Assembling a Car Like a Mechanic in Wrench
You can read all the manuals and watch hours of video, but nothing beats hands-on wrench-turning experience if you want to get better at understanding how your car works.